All In Biotech

Drug Trial Radar · NCT03010228

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Multivalent Recombinant OspA Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged Below 40 Years

Last checked: Nov 19, 2026Latest source record: Apr 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 179 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

179

Actual

Start

Jan 31, 2017

Primary completion

Sep 28, 2017

Study completion Jan 16, 2019

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Valneva Austria GmbH
First posted
Jan 4, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 39 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Observer-blind, partially randomized, multi-center dose escalation Phase I study in healthy adults below 40 years of age. 180 subjects will be enrolled in 6 treatment groups (different doses; different formulation: with/without adjuvant); vaccinations will be given I.M.(intramuscular) into the deltoid region on Days 0, 28 and 56. Study participants will be followed up until one year after first vaccination. Booster Extension: Subjects in the 48µg and 90µg Treatment groups who received a complete Primary immunization schedule will be included into a Booster Extension 13 months after the first immunization.

Conditions

  • Lyme Borreliosis, Nervous System

Interventions

  • VLA15 with AlumBiological

    I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses

  • VLA15 without AlumBiological

    I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of SAEs to Day 84Time frame: up to Day 84 (Month 3) after first vaccination
  2. Rate of related SAEs to Day 84Time frame: up to Day 84 (Month 3) after first vaccination
  3. Rate of any solicited or unsolicited Grade 3 or Grade 4 events up to Day 84Time frame: up to Day 84 (Month 3) after first vaccination
  4. Rate of any solicited or related unsolicited Grade 3 or Grade 4 events up to Day 84Time frame: up to Day 84 (Month 3) after first vaccination
  5. Rate of solicited local AEs within 7 days after each and after any vaccination up to Day 84Time frame: up to Day 84 (Month 3) after first vaccination
  6. Rate of solicited systemic AEs within 7 days after each and after any vaccination up to Day 84Time frame: up to Day 84 (Month 3) after first vaccination
  7. Rate of unsolicited AEs to Day 84, including clinically significant laboratory parameter changesTime frame: up to Day 84 (Month 3) after first vaccination
  8. Rate of related unsolicited AEs to Day 84, including clinically significant laboratory parameter changesTime frame: up to Day 84 (Month 3) after first vaccination

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • eStudy Site

    La Mesa, California

  • eStudySite

    La Mesa, California

  • Celerion Inc.

    Lincoln, Nebraska

  • Celerion, Inc

    Lincoln, Nebraska

  • University Hospital Ghent

    Ghent, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.